User:Ahmed Zaghw: Difference between revisions
Jump to navigation
Jump to search
Ahmed Zaghw (talk | contribs) (Created page with "Idiopathic interstitial pneumonia") |
Ahmed Zaghw (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
[[Idiopathic interstitial pneumonia]] | [[Idiopathic interstitial pneumonia]] | ||
{|class="wikitable" width="80%" | |||
|- | |||
| colspan="1" style="text-align:center; background:"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class I]] | |||
|- | |||
| bgcolor=""|<nowiki>"</nowiki>'''1. '''High-intensity statin therapy should be initiated or continued as first-line therapy in women and men ≤75 years of age who have clinical ASCVD, unless contraindicated.''([[ACC AHA guidelines classification scheme#Classification of Recommendations|Level of Evidence: A]])''<nowiki>"</nowiki> | |||
|- | |||
| bgcolor=|<nowiki>"</nowiki>'''2. '''In individuals with clinical ASCVD* in whom high-intensity statin therapy would otherwise be used, when high-intensity statin therapy is contraindicated† or when characteristics predisposing to statin-associated adverse effects are present, moderate-intensity statin should be used as the second option if tolerated.''([[ACC AHA guidelines classification scheme#Classification of Recommendations|Level of Evidence: A]])''<nowiki>"</nowiki> | |||
|- | |||
|} | |||
<table> | |||
{|class="wikitable" border="1" style="text-align:center; width:600px;" | |||
|-style="background:#CDC9C9" | |||
| Risk category | |||
| LDL goal, mg/dL | |||
|Non-HDL goal, mg/dL | |||
|- | |||
| CHD and CHD risk equivalent (10 year risk for CHD is >20%) | |||
| < 100 | |||
| < 130 | |||
|- | |||
| Multiple (2+) risk factor (10 year risk for CHD is <20%) | |||
| < 130 | |||
| < 160 | |||
|- | |||
| 0-1 risk factors | |||
| < 160 | |||
| < 190 | |||
|- | |||
|} | |||
ATP III LDL cholesterol and Non-HDL cholesterol goals <ref name="pmid11368702">{{cite journal| author=Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults| title=Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). | journal=JAMA | year= 2001 | volume= 285 | issue= 19 | pages= 2486-97 | pmid=11368702 | doi= | pmc= |url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11368702 }} </ref> | |||
{|class="wikitable" width="80%" | |||
|- | |||
| colspan="1" style="text-align:center; background:LightGreen"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class I]] | |||
|- | |||
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''1. '''Individuals with LDL–C ≥190 mg/dL or triglycerides ≥500 mg/dL should be evaluated for secondary causes of hyperlipidemia.''([[ACC AHA guidelines classification scheme#Classification of Recommendations|Level of Evidence: B]])''<nowiki>"</nowiki> | |||
|- | |||
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''2. '''Adults ≥21 years of age with primary LDL–C ≥190 mg/dL should be treated with statin therapy (10-year ASCVD risk estimation is not required): <BR> | |||
* Use high-intensity statin therapy unless contraindicated. <BR> | |||
* For individuals unable to tolerate high-intensity statin therapy, use the maximum tolerated statin intensity.''([[ACC AHA guidelines classification scheme#Classification of Recommendations|Level of Evidence: B]])''<nowiki>"</nowiki> | |||
|- | |||
|} | |||
==References== | |||
{{Reflist|2}} | |||
Revision as of 17:12, 13 November 2013
Idiopathic interstitial pneumonia
| Class I |
| "1. High-intensity statin therapy should be initiated or continued as first-line therapy in women and men ≤75 years of age who have clinical ASCVD, unless contraindicated.(Level of Evidence: A)" |
| "2. In individuals with clinical ASCVD* in whom high-intensity statin therapy would otherwise be used, when high-intensity statin therapy is contraindicated† or when characteristics predisposing to statin-associated adverse effects are present, moderate-intensity statin should be used as the second option if tolerated.(Level of Evidence: A)" |
| Risk category | LDL goal, mg/dL | Non-HDL goal, mg/dL |
| CHD and CHD risk equivalent (10 year risk for CHD is >20%) | < 100 | < 130 |
| Multiple (2+) risk factor (10 year risk for CHD is <20%) | < 130 | < 160 |
| 0-1 risk factors | < 160 | < 190 |
ATP III LDL cholesterol and Non-HDL cholesterol goals [1]
| Class I |
| "1. Individuals with LDL–C ≥190 mg/dL or triglycerides ≥500 mg/dL should be evaluated for secondary causes of hyperlipidemia.(Level of Evidence: B)" |
"2. Adults ≥21 years of age with primary LDL–C ≥190 mg/dL should be treated with statin therapy (10-year ASCVD risk estimation is not required):
|
References
- ↑ Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001). "Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)". JAMA. 285 (19): 2486–97. PMID 11368702.